Arcturus Therapeutics Holdings Inc ARCT
News
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics Shares Rise on Plans to Work with Thermo Fisher Scientific on Cystic Fibrosis Drug
